Advertisement
Advertisement
U.S. Markets open in 8 hrs 23 mins
Advertisement
Advertisement
Advertisement
Advertisement

Pluristem Therapeutics Inc. (PSTI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6500+0.1800 (+7.29%)
At close: 4:00PM EDT
Advertisement

Pluristem Therapeutics Inc.

Building No. 5
MATAM Advanced Technology Park
Haifa 3508409
Israel
972 7 4710 8600
http://www.pluristem.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees153

Key Executives

NameTitlePayExercisedYear Born
Mr. Zami AbermanExec. Chairman1.06MN/A1954
Mr. Yaacov YanayPres, CEO & Director612.6kN/A1971
Ms. Chen Franco-YehudaCFO, Treasurer & Sec.330.3kN/A1984
Mr. Lior RavivVP of Operations & Devel.N/AN/AN/A
Ms. Dana RubinDirector of Investor RelationsN/AN/AN/A
Ms. Efrat Livne-HadassVP of HRN/AN/AN/A
Dr. Nitsan Halevy M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Corporate Governance

Pluristem Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement